Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease

PURPOSE: As several therapies aimed at lowering mutant huntingtin (mHTT) brain levels in Huntington’s disease (HD) are currently being investigated, noninvasive positron emission tomography (PET) imaging of mHTT could be utilized to directly evaluate therapeutic efficacy and monitor disease progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoglio, Daniele, Verhaeghe, Jeroen, Miranda, Alan, Wyffels, Leonie, Stroobants, Sigrid, Mrzljak, Ladislav, Khetarpal, Vinod, Skinbjerg, Mette, Liu, Longbin, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Bard, Jonathan, Staelens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921134/
https://www.ncbi.nlm.nih.gov/pubmed/34651228
http://dx.doi.org/10.1007/s00259-021-05578-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921134/
https://www.ncbi.nlm.nih.gov/pubmed/34651228
http://dx.doi.org/10.1007/s00259-021-05578-8

Ejemplares similares